Scienture Expands Access to ARBLI and Prepares for Launch of REZENOPY in 2026

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI™ (losartan potassium) oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook—including reaffirming its plan to commercially launch REZENOPY™, a life-saving opioid overdose emergency treatment, in the second quarter of 2026.

Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to ARBLI™ across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions (IQVIA MAT Dec 2025) U.S. losartan market.

Key highlights:

• Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for ARBLI™
• Executed multiple Institutional GPO agreements, expanding U.S. access to more than 2,500 healthcare institutions nationwide
• Achieved formulary inclusion with major national health plans, expanding coverage to over 100 million covered lives
• Established a strategic collaboration with BlinkRx, enhancing patient access, fulfillment, and adherence through a streamlined digital pharmacy and hub service platform
  
  
  
   

"These milestones significantly expand the commercial opportunity for ARBLI™ and represent an important inflection point in its launch trajectory," commented Narasimhan Mani, President and co-CEO of Scienture. "By securing GPO agreements, expanding formulary inclusion, and partnering with BlinkRx, we are significantly increasing the number of patients and providers who can readily access ARBLI™."

Looking ahead to the first quarter of 2026, Scienture expects:

• Continued sequential growth in ARBLI™ prescription volumes and product adoption
• Improved commercial efficiency, as early launch investments translate into recurring demand
• Further expansion of payer and pharmacy engagement, supporting broader patient access across commercial and government sectors
  
  
  
   

"We are encouraged by the steady progress we've made with ARBLI™ since launch," stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. "The last four months have validated the unmet need for a ready-to-use oral suspension of losartan, and we believe Q1 2026 will reflect the momentum we've built across prescriber adoption, distribution, and patient demand."

Scienture reaffirms its plan to commercially launch REZENOPY™, a life-saving opioid overdose emergency treatment in the second quarter of 2026, representing the Company's second product launch in the US market for naloxone (IQVIA MAT Dec 2025 of $143 million and 9.2 million (eaches) in total annual sales and volume respectively). Management believes REZENOPY™ will leverage Scienture's expanding commercial infrastructure and access footprint established through ARBLI™.

"Our progress with ARBLI™ has laid the groundwork for a scalable, multi-product commercial platform. With REZENOPY™ planned for launch in the first quarter of 2026, we believe Scienture is entering its next phase of growth. Importantly, during Q4 2025, we fundamentally strengthened our balance sheet through a substantial reduction in outstanding debt and a meaningful improvement in our cash resources . As of December 31, 2025, the Company had a cash position of approximately $7.0 million. With an optimized capital structure, we believe we are now well positioned and adequately capitalized to execute our commercial strategy, support the continued growth of ARBLI™, and advance our key operational and pipeline objectives," concluded Narasimhan Mani, President and co-CEO of Scienture.